JP2020516693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516693A5 JP2020516693A5 JP2020506298A JP2020506298A JP2020516693A5 JP 2020516693 A5 JP2020516693 A5 JP 2020516693A5 JP 2020506298 A JP2020506298 A JP 2020506298A JP 2020506298 A JP2020506298 A JP 2020506298A JP 2020516693 A5 JP2020516693 A5 JP 2020516693A5
- Authority
- JP
- Japan
- Prior art keywords
- parpi
- cancer
- combination
- sra737
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 75
- 239000012661 PARP inhibitor Substances 0.000 claims description 73
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 73
- YBYYWUUUGCNAHQ-LLVKDONJSA-N 5-[[4-[[(2r)-morpholin-2-yl]methylamino]-5-(trifluoromethyl)pyridin-2-yl]amino]pyrazine-2-carbonitrile Chemical compound C1=C(NC[C@@H]2OCCNC2)C(C(F)(F)F)=CN=C1NC1=CN=C(C#N)C=N1 YBYYWUUUGCNAHQ-LLVKDONJSA-N 0.000 claims description 51
- 230000004614 tumor growth Effects 0.000 claims description 46
- 239000003112 inhibitor Substances 0.000 claims description 34
- 101150113535 chek1 gene Proteins 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 24
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 230000005764 inhibitory process Effects 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 14
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 14
- 229960000572 olaparib Drugs 0.000 claims description 14
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims description 12
- 238000011260 co-administration Methods 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims description 9
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims description 9
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 230000006801 homologous recombination Effects 0.000 claims description 8
- 238000002744 homologous recombination Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 claims description 6
- CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 claims description 6
- 241000173529 Aconitum napellus Species 0.000 claims description 6
- 108700020463 BRCA1 Proteins 0.000 claims description 6
- 102000036365 BRCA1 Human genes 0.000 claims description 6
- 101150072950 BRCA1 gene Proteins 0.000 claims description 6
- 108700020462 BRCA2 Proteins 0.000 claims description 6
- 102000052609 BRCA2 Human genes 0.000 claims description 6
- 101150008921 Brca2 gene Proteins 0.000 claims description 6
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 6
- 229940023019 aconite Drugs 0.000 claims description 6
- 229950002133 iniparib Drugs 0.000 claims description 6
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 6
- IAYGCINLNONXHY-LBPRGKRZSA-N 3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-3-piperidinyl]-2-thiophenecarboxamide Chemical compound NC(=O)NC=1C=C(C=2C=C(F)C=CC=2)SC=1C(=O)N[C@H]1CCCNC1 IAYGCINLNONXHY-LBPRGKRZSA-N 0.000 claims description 4
- MOVBBVMDHIRCTG-LJQANCHMSA-N 4-[(3s)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1h-benzimidazol-2-yl)-6-chloroquinolin-2(1h)-one Chemical compound C([N@](CC1)C2)C[C@@H]1[C@@H]2NC1=C(C=2NC3=CC=CC=C3N=2)C(=O)NC2=CC=C(Cl)C=C21 MOVBBVMDHIRCTG-LJQANCHMSA-N 0.000 claims description 4
- GMIZZEXBPRLVIV-SECBINFHSA-N 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3r)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=NN(C)C=C1C1=C2N=C([C@H]3CNCCC3)C(Br)=C(N)N2N=C1 GMIZZEXBPRLVIV-SECBINFHSA-N 0.000 claims description 4
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 claims description 4
- 102000000872 ATM Human genes 0.000 claims description 4
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 102100035631 Bloom syndrome protein Human genes 0.000 claims description 4
- 108091009167 Bloom syndrome protein Proteins 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims description 4
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims description 4
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 claims description 4
- 102100039116 DNA repair protein RAD50 Human genes 0.000 claims description 4
- 102100033934 DNA repair protein RAD51 homolog 2 Human genes 0.000 claims description 4
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 claims description 4
- 102100034483 DNA repair protein RAD51 homolog 4 Human genes 0.000 claims description 4
- 102100027830 DNA repair protein XRCC2 Human genes 0.000 claims description 4
- 102100027829 DNA repair protein XRCC3 Human genes 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 102000009095 Fanconi Anemia Complementation Group A protein Human genes 0.000 claims description 4
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 claims description 4
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 claims description 4
- 108010027673 Fanconi Anemia Complementation Group C protein Proteins 0.000 claims description 4
- 102000013601 Fanconi Anemia Complementation Group D2 protein Human genes 0.000 claims description 4
- 108010026653 Fanconi Anemia Complementation Group D2 protein Proteins 0.000 claims description 4
- 102000010634 Fanconi Anemia Complementation Group E protein Human genes 0.000 claims description 4
- 108010077898 Fanconi Anemia Complementation Group E protein Proteins 0.000 claims description 4
- 102000012216 Fanconi Anemia Complementation Group F protein Human genes 0.000 claims description 4
- 108010022012 Fanconi Anemia Complementation Group F protein Proteins 0.000 claims description 4
- 102000007122 Fanconi Anemia Complementation Group G protein Human genes 0.000 claims description 4
- 108010033305 Fanconi Anemia Complementation Group G protein Proteins 0.000 claims description 4
- 102000052930 Fanconi Anemia Complementation Group L protein Human genes 0.000 claims description 4
- 108700026162 Fanconi Anemia Complementation Group L protein Proteins 0.000 claims description 4
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 claims description 4
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 claims description 4
- 102100034554 Fanconi anemia group I protein Human genes 0.000 claims description 4
- 102100034553 Fanconi anemia group J protein Human genes 0.000 claims description 4
- 102100034552 Fanconi anemia group M protein Human genes 0.000 claims description 4
- 102100039999 Histone deacetylase 2 Human genes 0.000 claims description 4
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 claims description 4
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims description 4
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 claims description 4
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims description 4
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims description 4
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 claims description 4
- 101000712511 Homo sapiens DNA repair and recombination protein RAD54-like Proteins 0.000 claims description 4
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 claims description 4
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 claims description 4
- 101001132266 Homo sapiens DNA repair protein RAD51 homolog 4 Proteins 0.000 claims description 4
- 101000649306 Homo sapiens DNA repair protein XRCC2 Proteins 0.000 claims description 4
- 101000729474 Homo sapiens DNA-directed RNA polymerase I subunit RPA1 Proteins 0.000 claims description 4
- 101100119754 Homo sapiens FANCL gene Proteins 0.000 claims description 4
- 101000848174 Homo sapiens Fanconi anemia group I protein Proteins 0.000 claims description 4
- 101000848171 Homo sapiens Fanconi anemia group J protein Proteins 0.000 claims description 4
- 101000848187 Homo sapiens Fanconi anemia group M protein Proteins 0.000 claims description 4
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 claims description 4
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 claims description 4
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims description 4
- 101001092125 Homo sapiens Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 claims description 4
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims description 4
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 229910015837 MSH2 Inorganic materials 0.000 claims description 4
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 claims description 4
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 101100355599 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-11 gene Proteins 0.000 claims description 4
- YFNWWNRZJGMDBR-LJQANCHMSA-N PF-00477736 Chemical compound C1=NN(C)C=C1C1=NC2=CC(NC(=O)[C@H](N)C3CCCCC3)=CC3=C2C1=CNNC3=O YFNWWNRZJGMDBR-LJQANCHMSA-N 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 102000001195 RAD51 Human genes 0.000 claims description 4
- 101710018890 RAD51B Proteins 0.000 claims description 4
- 101150006234 RAD52 gene Proteins 0.000 claims description 4
- 108010068097 Rad51 Recombinase Proteins 0.000 claims description 4
- 102000053062 Rad52 DNA Repair and Recombination Human genes 0.000 claims description 4
- 108700031762 Rad52 DNA Repair and Recombination Proteins 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 102100035729 Replication protein A 70 kDa DNA-binding subunit Human genes 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims description 4
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 claims description 4
- 102000000504 Tumor Suppressor p53-Binding Protein 1 Human genes 0.000 claims description 4
- 108010041385 Tumor Suppressor p53-Binding Protein 1 Proteins 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 108010074310 X-ray repair cross complementing protein 3 Proteins 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000000112 colonic effect Effects 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 230000028617 response to DNA damage stimulus Effects 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- SRBJWIBAMIKCMV-GFCCVEGCSA-N 5-[(8-chloroisoquinolin-3-yl)amino]-3-[(2r)-1-(dimethylamino)propan-2-yl]oxypyrazine-2-carbonitrile Chemical group N1=C(C#N)C(O[C@@H](CN(C)C)C)=NC(NC=2N=CC3=C(Cl)C=CC=C3C=2)=C1 SRBJWIBAMIKCMV-GFCCVEGCSA-N 0.000 claims description 2
- 101000583811 Homo sapiens Mitotic spindle assembly checkpoint protein MAD2B Proteins 0.000 claims description 2
- 102100030955 Mitotic spindle assembly checkpoint protein MAD2B Human genes 0.000 claims description 2
- -1 SAR-021066 Chemical compound 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483888P | 2017-04-10 | 2017-04-10 | |
| US62/483,888 | 2017-04-10 | ||
| US201762552364P | 2017-08-30 | 2017-08-30 | |
| US62/552,364 | 2017-08-30 | ||
| US201862614268P | 2018-01-05 | 2018-01-05 | |
| US62/614,268 | 2018-01-05 | ||
| US201862635394P | 2018-02-26 | 2018-02-26 | |
| US62/635,394 | 2018-02-26 | ||
| US201862650185P | 2018-03-29 | 2018-03-29 | |
| US62/650,185 | 2018-03-29 | ||
| PCT/US2018/026917 WO2018191277A1 (en) | 2017-04-10 | 2018-04-10 | Chk1 (sra737)/parpi combination methods of inhibiting tumor growth |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516693A JP2020516693A (ja) | 2020-06-11 |
| JP2020516693A5 true JP2020516693A5 (https=) | 2021-03-25 |
| JP7273791B2 JP7273791B2 (ja) | 2023-05-15 |
Family
ID=63793688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506298A Active JP7273791B2 (ja) | 2017-04-10 | 2018-04-10 | 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11596637B2 (https=) |
| EP (1) | EP3609884A4 (https=) |
| JP (1) | JP7273791B2 (https=) |
| KR (1) | KR102645511B1 (https=) |
| CN (2) | CN110582490A (https=) |
| AU (2) | AU2018250552B2 (https=) |
| CA (1) | CA3059576A1 (https=) |
| MX (1) | MX2019012176A (https=) |
| WO (1) | WO2018191277A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3065803A1 (en) * | 2017-06-01 | 2018-12-06 | Sierra Oncology, Inc. | Biomarkers and patient selection strategies |
| CA3092079A1 (en) * | 2018-02-26 | 2019-08-29 | Sierra Oncology, Inc. | Methods of treatment of cancer comprising chk1 inhibitors |
| WO2020198510A1 (en) * | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| US20220226338A1 (en) * | 2019-05-14 | 2022-07-21 | Sierra Oncology, Inc. | Methods of Treating Cancer Using CHK1 Inhibitors |
| KR102285996B1 (ko) * | 2019-08-08 | 2021-08-05 | 차의과학대학교 산학협력단 | 혈관신생을 억제하는 데 사용하기 위한 조성물 및 그 용도 |
| EP4087563A4 (en) * | 2020-01-07 | 2024-03-27 | Shanghai Huayu Biotechnology Co., Ltd. | COMBINATION CANCER THERAPY WITH CHK INHIBITOR |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| AU2021325905A1 (en) | 2020-08-12 | 2023-04-13 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
| KR20230146593A (ko) * | 2021-02-16 | 2023-10-19 | 리본 테라퓨틱스 인코포레이티드 | Parp7 억제제에 대한 투여량 레지멘 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US20050250836A1 (en) * | 2004-05-03 | 2005-11-10 | Pfizer Inc | Inhibitors of checkpoint kinases (Wee1 and Chk1) |
| CN101743003A (zh) | 2007-05-25 | 2010-06-16 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的chk和parp抑制剂的组合 |
| WO2009099601A2 (en) | 2008-02-04 | 2009-08-13 | Dana-Farber Cancer Institute, Inc. | Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3 |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| ES2621857T3 (es) * | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| RU2659786C2 (ru) | 2012-05-15 | 2018-07-04 | Кансер Ресёрч Текнолоджи Лимитед | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения |
| WO2014062454A1 (en) * | 2012-10-15 | 2014-04-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| GB201316526D0 (en) | 2013-09-17 | 2013-10-30 | King S College London | Biomarkers |
| WO2015077602A1 (en) | 2013-11-22 | 2015-05-28 | Fred Hutchinson Cancer Research Center | Methods for identifying therapeutic targets and treating and monitoring cancers |
| WO2018191299A1 (en) | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth |
| CA3065803A1 (en) | 2017-06-01 | 2018-12-06 | Sierra Oncology, Inc. | Biomarkers and patient selection strategies |
| CA3092079A1 (en) | 2018-02-26 | 2019-08-29 | Sierra Oncology, Inc. | Methods of treatment of cancer comprising chk1 inhibitors |
-
2018
- 2018-04-10 EP EP18784295.0A patent/EP3609884A4/en active Pending
- 2018-04-10 JP JP2020506298A patent/JP7273791B2/ja active Active
- 2018-04-10 US US16/604,116 patent/US11596637B2/en active Active
- 2018-04-10 AU AU2018250552A patent/AU2018250552B2/en active Active
- 2018-04-10 WO PCT/US2018/026917 patent/WO2018191277A1/en not_active Ceased
- 2018-04-10 CN CN201880024426.7A patent/CN110582490A/zh active Pending
- 2018-04-10 KR KR1020197033136A patent/KR102645511B1/ko active Active
- 2018-04-10 CN CN202311004815.2A patent/CN116999564A/zh active Pending
- 2018-04-10 MX MX2019012176A patent/MX2019012176A/es unknown
- 2018-04-10 CA CA3059576A patent/CA3059576A1/en active Pending
-
2022
- 2022-10-27 AU AU2022259818A patent/AU2022259818A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516693A5 (https=) | ||
| Li et al. | A new wave of innovations within the DNA damage response | |
| Sachdev et al. | PARP inhibition in cancer: an update on clinical development | |
| Ferraris | Evolution of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic | |
| JP2017516784A5 (https=) | ||
| Bouwman et al. | Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? | |
| CN101981013B (zh) | 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮 | |
| EP3594343B1 (en) | Use of a combination of dbait molecule and parp inhibitors to treat cancer | |
| CN105120663B (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| CA3054246A1 (en) | An inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease | |
| CA2869557A1 (en) | Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment | |
| US11224608B2 (en) | Compounds and methods for treating cancer | |
| US20200157638A1 (en) | Biomarkers and patient selection strategies | |
| TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| FI3386546T3 (fi) | Yhdistelmä metastaattisen syövän tehokkaaseen hoitoon potilailla | |
| JP2019501962A5 (https=) | ||
| Li et al. | The G-quadruplex ligand CX-5461: an innovative candidate for disease treatment | |
| Ji et al. | Super-enhancers in tumors: unraveling recent advances in their role in oncogenesis and the emergence of targeted therapies | |
| JP2004524349A5 (https=) | ||
| JP2018535186A (ja) | がん治療におけるウレイドマスチン（ｂｏ−１０５５）の使用 | |
| Kaiser et al. | Hypusinated EIF5A as a feasible drug target for Advanced Medicinal Therapies in the treatment of pathogenic parasites and therapy-resistant tumors | |
| JP2020528418A (ja) | ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法 | |
| EP3999050A2 (en) | Combination therapy for cancer treatment | |
| Cao et al. | Poly (ADP-Ribosyl) polymerase 1 inhibitors: A patent review | |
| Haber | Pre-Clinical Investigations of the Second-Generation Polymeric Fluoropyrimidine, ARAC-FdUMP [10](CF10), for the Treatment of Gastrointestinal Cancers |